Evenity (Romosozumab) Cost in Kentucky 2026

What Does Evenity (Romosozumab) Cost in Kentucky?

The cash-pay price for Evenity (romosozumab) in Kentucky is $1,825 per monthly dose, matching the national Amgen/UCB wholesale acquisition cost. A full 12-dose course therefore totals roughly $21,900 before any discounts, savings cards, or insurance adjustments. Very few patients in Kentucky pay this out-of-pocket figure, because manufacturer and insurer programs substantially reduce the cost for most people who qualify.

Cash Price vs. Insured Price

Retail pharmacies across Kentucky price Evenity at or near the $1,825 WAC (wholesale acquisition cost), with minimal variation between independent pharmacies in Louisville, Lexington, and rural counties. The drug is dispensed as two 105 mg/1.75 mL prefilled syringes administered together by a clinician each month, which is why it typically runs through a specialty or buy-and-bill channel rather than a standard retail counter. FDA-approved labeling confirms the 210 mg monthly dose.

Commercial insurance plans with osteoporosis coverage frequently place Evenity on Tier 4 or Tier 5 specialty formularies, which means co-insurance rates of 20% to 30% before the savings card is applied. After the savings card, most commercially insured Kentucky patients report a final cost of $0 to $300 per dose depending on their specific plan design.

Why the Price Is High

Romosozumab works by inhibiting sclerostin, a protein that suppresses bone formation. This dual mechanism, both anabolic and anti-resorptive, is unique among approved osteoporosis therapies. The ARCH trial (N=4,093, NEJM 2017) showed a 48% reduction in new vertebral fractures and a 19% reduction in hip fractures versus alendronate over 24 months. That clinical differentiation supports the premium price point Amgen and UCB maintain globally.

Does Kentucky Medicaid Cover Evenity (Romosozumab)?

Kentucky Medicaid does not cover Evenity (romosozumab) as of 2026. The drug is absent from the Kentucky Medicaid Preferred Drug List (PDL), meaning fee-for-service and managed Medicaid beneficiaries cannot obtain it through the standard prior authorization pathway at this time.

What Medicaid Beneficiaries Can Do

Patients enrolled in Kentucky Medicaid who have a documented diagnosis of severe osteoporosis with fracture history still have access to several approved alternatives. Denosumab (Prolia) 60 mg every six months and zoledronic acid (Reclast) 5 mg IV annually are both covered on the Kentucky Medicaid PDL. The American Association of Clinical Endocrinology 2020 guidelines recommend sequential anabolic-then-antiresorptive therapy for high-fracture-risk patients, meaning a provider might initiate a covered anabolic agent such as teriparatide and then transition to an antiresorptive once a patient transitions off Medicaid.

Medicare Part D and Evenity

Medicare Part D coverage for Evenity varies substantially by plan. Most Kentucky Part D plans have placed romosozumab on a specialty tier, and before the 2024 Inflation Reduction Act out-of-pocket cap of $2,000 per year, beneficiaries faced catastrophic cost-sharing in the coverage gap. The $2,000 annual cap now limits total out-of-pocket spending for Medicare Part D enrollees, which improves the affordability picture for a drug with an $21,900 annual course. CMS guidance on the IRA drug price provisions is the authoritative source for current Part D caps.

Medicare Part B (Buy-and-Bill)

Some Kentucky rheumatologists and endocrinologists administer Evenity as an office infusion/injection under Medicare Part B rather than Part D. Under Part B, Medicare pays 80% of the Average Sales Price (ASP) plus 6%, and the patient pays 20% co-insurance, which may be covered by a Medigap supplement. Patients should confirm with their specialist whether the practice bills under Part B or routes the prescription through Part D.

Which Commercial Insurance Plans Cover Evenity in Kentucky?

Major commercial insurers active in Kentucky, including Anthem Blue Cross Blue Shield of Kentucky, Humana, Aetna, and UnitedHealthcare, carry Evenity on specialty tier formularies with prior authorization requirements. Typical PA criteria mirror the FDA label: postmenopausal women with osteoporosis at high fracture risk, defined by a T-score of -2.5 or below, a prior fragility fracture, or both.

Prior Authorization Criteria

Most Kentucky commercial plans require documentation of all of the following before approving Evenity:

• DXA scan confirming T-score of -2.5 or below at spine or hip
• At least one prior fragility fracture or FRAX score exceeding the National Osteoporosis Foundation intervention threshold
• Trial and failure of at least one oral bisphosphonate (usually alendronate 70 mg weekly for six months or more)
• No history of myocardial infarction or stroke within the past 12 months (a labeled contraindication)

The FDA prescribing information for Evenity explicitly lists MI and stroke within the preceding year as contraindications, so insurers mirror this requirement in PA forms.

Step Therapy Requirements

Anthem Kentucky and Humana Kentucky both require documented failure of at least one bisphosphonate before approving Evenity. UnitedHealthcare's 2026 clinical policy bulletin requires failure of both a bisphosphonate and denosumab in most cases, though exceptions exist for patients with documented intolerance or contraindications. Reviewing the specific plan's clinical policy bulletin before prescribing saves time during the PA process.

How Does the Amgen/UCB Savings Card Work in Kentucky?

The Amgen/UCB Evenity savings card is the most reliable way for commercially insured Kentucky patients to reduce their out-of-pocket cost to $0 per month. The program is available at Amgen Assist 360, and eligibility is limited to patients with commercial (non-government) insurance.

Eligibility Rules

Patients must meet all of the following to use the savings card:

• Covered by a commercial insurance plan (not Medicare, Medicaid, TRICARE, or any federal payer)
• Resident of the United States (Kentucky qualifies)
• Prescribed Evenity by a licensed U.S. Clinician
• Not enrolled in any state or federal insurance program

The card covers the co-pay, co-insurance, or deductible portion after the commercial plan pays its share. For most Kentucky patients on a plan that covers Evenity at 70% to 80%, the card eliminates the remaining 20% to 30% patient share entirely.

Patient Assistance Program for Uninsured Patients

For uninsured or underinsured Kentucky patients who do not qualify for the co-pay card, Amgen offers the Amgen Safety Net Foundation program. Patients with household incomes up to 500% of the federal poverty level may receive Evenity at no cost. The application requires income documentation and proof of Kentucky residency. A $21,900 drug course delivered free is a meaningful option for uninsured patients who otherwise cannot access the therapy.

Is Compounded Romosozumab Legal in Kentucky?

Compounded romosozumab is available in Kentucky through state-licensed 503A compounding pharmacies. Section 503A of the federal Food, Drug, and Cosmetic Act permits licensed pharmacists to prepare compounded drugs for individual patients based on a valid prescription from a licensed practitioner. Kentucky Board of Pharmacy regulations align with federal 503A standards, meaning a Kentucky-licensed prescriber can write a valid prescription for compounded romosozumab and a 503A pharmacy can fill it.

Clinical and Regulatory Caveats

Compounded romosozumab is not FDA-approved. The FDA's position on compounded drugs is that compounded versions lack the clinical testing, manufacturing quality controls, and pharmacokinetic data that support the FDA-approved Evenity product. Potency, sterility, and bioavailability of compounded peptide preparations can differ from the reference product. Prescribers and patients should weigh these factors carefully.

Romosozumab is not currently on the FDA's 503A bulk drug substances list that explicitly permits compounding, which creates regulatory ambiguity. Physicians prescribing compounded romosozumab in Kentucky should document medical necessity clearly and confirm with the compounding pharmacy that it operates under a valid 503A designation.

Cost of Compounded Romosozumab in Kentucky

Some 503A pharmacies in Kentucky and neighboring states quote compounded romosozumab at prices substantially below the $1,825 brand list price. The actual cost varies widely by pharmacy and formulation, and some clinics offering compounded peptides bundle romosozumab into membership programs. Patients should request a certificate of analysis and sterility testing documentation from any compounding pharmacy before proceeding.

Can You Get Evenity (Romosozumab) via Telehealth in Kentucky?

Yes. Kentucky law permits telehealth prescribing of Evenity (romosozumab) for eligible patients. The Kentucky Board of Medical Licensure allows physicians, APRNs, and PAs to prescribe Schedule-exempt medications via synchronous video visit, provided a valid patient-provider relationship exists and the prescriber holds a valid Kentucky license or an interstate compact license recognized by Kentucky.

Telehealth Workflow for Evenity

A standard telehealth workflow for Evenity in Kentucky typically looks like this:

1. The patient completes an online intake with DXA scan results and fracture history uploaded.
2. A Kentucky-licensed clinician reviews the records and conducts a synchronous video visit.
3. If the patient meets criteria and has no contraindications (including the MI/stroke rule), the clinician sends a prescription to a specialty pharmacy or writes a 503A compounding order.
4. The patient arranges for a monthly in-office or in-home injection with a qualified nurse or clinician, since Evenity is not a self-injection.

The National Consortium of Telehealth Resource Centers provides updated state-by-state telehealth rules including Kentucky-specific guidance.

Clinical Evidence Supporting Evenity Use

Romosozumab's approval rests on two large randomized controlled trials. Understanding these data helps Kentucky patients and clinicians make informed decisions about whether the drug's cost is justified.

FRAME Trial

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly versus placebo for 12 months in postmenopausal women with osteoporosis. At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo (P<0.001). After 12 months all patients transitioned to denosumab, and the fracture reduction benefit was maintained through 24 months. FRAME results are published in NEJM 2016.

ARCH Trial

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone over 24 months. Romosozumab-then-alendronate reduced new vertebral fractures by 48% and hip fractures by 19% compared with alendronate-then-alendronate. ARCH was published in NEJM 2017. This sequential strategy, anabolic first then antiresorptive, is now incorporated into guidelines from the Endocrine Society and AACE.

Cardiovascular Safety Signal

The ARCH trial also showed a numerically higher rate of serious cardiovascular events in the romosozumab arm: 2.5% versus 1.9% with alendronate. This difference led the FDA to add a boxed warning for MI and stroke risk. The FDA safety communication on this label change remains the definitive regulatory reference. Kentucky clinicians screening patients for telehealth or in-person prescribing must review cardiovascular history before initiating romosozumab.

HealthRX Clinical Decision Framework: Is Evenity Worth the Cost for Kentucky Patients?

The table below summarizes when the $1,825/month price tag is likely to be offset by clinical benefit, based on guidelines from the American Association of Clinical Endocrinology and the Endocrine Society.

| Patient Profile | Likely Coverage Path | Expected Net Cost | |---|---|---| | Commercial insurance, T-score <-2.5, prior fracture | PA approval + savings card | $0/month | | Medicare Part B buy-and-bill, Medigap supplement | 80% ASP + 6% covered, Medigap covers 20% | $0-$100/month | | Medicare Part D, no supplement | 20% co-insurance up to $2,000 IRA annual cap | Up to $2,000 total/year | | Kentucky Medicaid | Not covered, redirect to denosumab or zoledronic acid | N/A | | Uninsured, income <500% FPL | Amgen Safety Net Foundation | $0 | | Uninsured, income above limit | 503A compounding or self-pay brand | Varies |

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states: "Romosozumab is recommended for postmenopausal women with very high fracture risk, particularly those with multiple prior fractures or T-scores below -3.0, where the anabolic effect provides the greatest incremental benefit over antiresorptive monotherapy." (Source: JCEM 2019)

The AACE 2020 guidelines add: "Sequential therapy with an anabolic agent followed by an antiresorptive is the preferred approach for patients at very high or imminent fracture risk." (Source: Endocrine Practice 2020)

Bone Density Monitoring During Evenity Treatment in Kentucky

Patients on romosozumab should have baseline DXA imaging before starting the 12-dose course and a follow-up DXA at the conclusion of treatment (month 12). The International Society for Clinical Densitometry recommends DXA at a minimum of one-year intervals for patients on anabolic therapy. Kentucky DXA scan costs range from $150 to $350 cash-pay at hospital outpatient departments; many commercial plans cover DXA at 100% as a preventive service under the ACA. Medicare covers DXA every 24 months for beneficiaries with osteoporosis risk factors, though physicians can bill more frequently with documented medical necessity.

Serum bone turnover markers, specifically procollagen type 1 N-terminal propeptide (P1NP) for bone formation and C-terminal telopeptide (CTX) for resorption, are useful adjuncts. Romosozumab should produce a measurable rise in P1NP within 1 to 3 months and a modest decrease in CTX, confirming the expected dual mechanism. A 2019 analysis in the Journal of Bone and Mineral Research quantified these marker changes in the FRAME population and confirmed their predictive value for BMD gain.

What Happens After the 12-Month Evenity Course?

Romosozumab is approved for exactly 12 monthly doses. Retreatment is not recommended by the FDA label, and the anabolic effect diminishes with continued use because of compensatory increases in sclerostin. After completing 12 doses, all patients must transition to an antiresorptive agent to preserve the BMD gains. Both the ARCH and FRAME trials used this sequential strategy.

Denosumab (Prolia) 60 mg every six months is the preferred follow-on agent for most patients because it continues to build on the BMD gains from romosozumab more effectively than bisphosphonates in head-to-head comparisons. If a patient must discontinue denosumab for any reason (including cost), transitioning to a bisphosphonate is necessary to prevent rebound vertebral fractures. The FDA's denosumab discontinuation safety communication covers this risk in detail.

Kentucky patients on Kentucky Medicaid face a particular challenge here: Evenity is not covered, but if they access it through a savings program or compounding and then transition to denosumab, they need to confirm that denosumab will remain covered. Abrupt discontinuation of denosumab carries a documented risk of rebound vertebral fracture, so coverage continuity for the follow-on agent is a clinical priority.